Sepiapterin - PTC Therapeutics
Alternative Names: CNSA 001; PTC-923; SephienceLatest Information Update: 24 Feb 2026
At a glance
- Originator Censa Pharmaceuticals
- Developer Censa Pharmaceuticals; PTC Therapeutics
- Class Amines; Gastrokinetics; Ketones; Pteridines; Small molecules; Urologics
- Mechanism of Action Phenylalanine hydroxylase stimulants
-
Orphan Drug Status
Yes - Phenylketonuria
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Phenylketonuria
- Preclinical Lupus nephritis
- Discontinued Diabetic gastroparesis; Dystonia
Most Recent Events
- 19 Feb 2026 PTC Therapeutics plans approval of Sepiapterin in Brazil in 2026
- 01 Feb 2026 Registered for Phenylketonuria (In adults, In children, In adolescents, In the elderly) in Brazil (PO)
- 22 Dec 2025 Registered for Phenylketonuria (In the elderly, In adolescents, In children, In adults) in Japan (PO)